LRRK2 kinase inhibitors are currently in phase 1 and 2 clinical trials with PD patients (Azeggagh & Berwick, 2021), while alternative strategies to antagonize LRRK2 signalling could be beneficial for future therapeutics. Here, LRRK2 is linked to Parkinson disease.